CD4 and neoplasm: In this scenario, the anti-tumor response of CD26hi T cells was superior to other CD4 T-cell subsets such as TH17 and bulk CD4+ T cells and did not require CD8+ T cells indicative of a direct tumor-lysing capacity [90].